Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.430
-0.110 (-4.33%)
At close: Aug 28, 2026, 4:00 PM EDT
2.430
-0.001 (-0.02%)
After-hours: Aug 28, 2026, 7:48 PM EDT

Fate Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6.496.6513.6363.5396.355.85
Revenue Growth
-23.36%-51.24%-78.55%-34.03%72.44%77.66%
Gross Profit
-77.93-85.25-104.9-93.65-224.15-159.67
Operating Income
-132.49-146.6-195.54-190.51-308.39-216.99
Net Income
-126-136.32-186.26-160.93-281.72-212.15
Earnings Per Share
-1.05-1.15-1.64-1.64-2.91-2.24
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
153.77203.66279.07315.18436.23615.91
Total Debt
75.6877.8585.27103.54109.34114.82
Net Cash (Debt)
78.1125.81193.8211.64326.89501.09
Net Cash Growth
-44.81%-35.09%-8.43%-35.26%-34.77%29.95%
Net Cash Per Share
0.651.061.702.153.385.29

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-101.94-106.08-122.87-132.26-248.21-162.87
Capital Expenditures
-3.71-5.95-0.73-6.15-35.57-50.7
Free Cash Flow
-105.66-112.04-123.6-138.42-283.77-213.57
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----147.41%-232.77%-285.92%
Operating Margin
-2041.13%-2205.90%-1434.52%-299.86%-320.24%-388.56%
Pretax Margin
-1941.09%-2051.08%-1366.46%-253.30%-292.55%-379.89%
Profit Margin
-1941.09%-2051.08%-1366.46%-253.30%-292.55%-379.89%
FCF Margin
-1627.76%-1685.78%-906.79%-217.87%-294.68%-382.43%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
44.8617.0613.795.8010.18100.05